Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$3.24 USD
-0.07 (-2.11%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $3.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Kyverna Therapeutics, Inc. has a market cap of $143.05M, which represents its share price of $3.31 multiplied by its outstanding shares number of 43.22M. As a small-cap company, KYTX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
KYTX 3.24 -0.07(-2.11%)
Will KYTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KYTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KYTX
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock
KYTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KYTX
Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise | ...
12 Health Care Stocks Moving In Tuesday's Intraday Session
Kyverna Therapeutics appoints Marc Grasso as CFO
Kyverna Therapeutics Announces Appointment of New Chief Financial Officer | KYTX Stock News
Kyverna Therapeutics names Marc Grasso, M.D., as CFO